Chordia Therapeutics’ Successful CTX-712 Trial Results

Chordia Therapeutics Inc. (JP:190A) has released an update.

Chordia Therapeutics Inc. reported promising results from a Japanese Phase 1 clinical trial of their CLK inhibitor, CTX-712, showing a 42.9% response rate among patients with hematologic malignancies. The drug was generally well-tolerated with manageable side effects, primarily gastrointestinal. Notably, patients with specific genetic mutations showed a higher response rate, suggesting the potential for patient stratification to improve outcomes.

For further insights into JP:190A stock, check out TipRanks’ Stock Analysis page.